Skip to content
Dose Brief
Menu

Human+ Status Review — GLP-1 Listings and Unresolved Terms

By Updated

Human+ now presents liver-focused GLP-1 care, but its policy links return to the homepage and current program terms remain unconfirmed.

Historical Brief Score65/100Recorded grade CDirectory position by recorded score: 256
Read Human+ public program information View current availability and member information.
Medication pricing

Current medication quote unconfirmed

Earlier listing from June 2026: Not disclosed.

Current enrollment, selected prescription and payment terms remain unconfirmed.

Semaglutide: full details

Current Human+ enrollment and medication quote unknown; earlier June 2026 listing: Not disclosed

Tirzepatide: full details

Current Human+ enrollment and medication quote unknown; earlier June 2026 listing: Not disclosed

Current availability
Homepage advertises all 50 states and DC, subject to treatment and clinician eligibility; actual selected-program access remains unconfirmed.
Prescription offer
Current prescription offer unconfirmed
AvailabilityPrescription availability unconfirmed— Current payment and cancellation terms remain unconfirmed. The June 2026 record disclosed no medication price and does not establish today’s membership arrangement.

Human+ in depth

A different program description

Human+ currently presents a liver-focused GLP-1 program rather than the earlier pharmacy-wholesale membership description. Its homepage names compounded semaglutide injections, tirzepatide injections and an oral tirzepatide option, with further oral links in the footer. Those are advertised choices, not confirmation that a particular patient can enroll or receive any of them. The earlier June 2026 listing disclosed no semaglutide or tirzepatide price.

The public page says there are no membership fees or dose upcharges, but its pricing, terms, refund and medical-consent links return to the homepage. That leaves the actual charge, renewal period and cancellation agreement unresolved. The page title also calls itself a mobile homepage mockup. These observations justify checking the terms directly; they do not prove that the business is closed or that no clinical service exists.

Named partners do not replace an agreement

The homepage names DrTelx, references CareGLP-affiliated medical practices elsewhere, and lists EPIQ Scripts, Foothills and Emerald as pharmacy partners. Readers still need the legal name of the practice and pharmacy assigned to their own care. Our pharmacy checklist explains those distinctions. The page’s liver-health claims and promotional images are not independent evidence of a patient’s likely outcome or of the credentials of the person treating them.

Before relying on this program, obtain its complete payment and consent documents, the clinician’s eligibility decision for your state and a usable cancellation contact. The advertised nationwide reach is qualified by clinical and medication availability. Our billing guide identifies the information needed for a comparable quote; until those details are supplied, the historical listing should not be treated as a current offer.

Sources we checked

Public program pages and terms, checked November 2026. We have not enrolled in treatment or independently tested the medication.

This source update covers the review text and stated program terms. The existing numerical score has not been recalculated from this check; it should not be read as a new validation of every score factor.

Historical score

Retained from the earlier program listing; this score does not rate current prescription availability. See the methodology.

Price Stability40/100
Supply Reliability77/100
Transparency63/100
Access Breadth70/100
Clinical Oversight83/100
Track Record70/100

What the sources establish

  • Homepage identifies advertised injectable and oral compounded options
  • Page names clinical and pharmacy relationships for readers to confirm

What still needs checking

  • Pricing and policy links return to the homepage rather than complete program terms
  • No current medication-specific payment, renewal or refund agreement is established
  • Named organizations and promotional health claims are not independent clinical verification

The brief

Useful for: Readers checking what Human+ currently advertises before relying on an earlier membership description. Human+ now presents liver-focused GLP-1 care, but its policy links return to the homepage and current program terms remain unconfirmed.

The score above is a historical assessment of the earlier listing, not a recommendation for current treatment. Compare current provider information before choosing care.

Before you decide

The questions readers ask next after reading about Human+.

Closest here

Directory neighbors by retained score; a status assessment does not establish current prescription availability.

Weighing Human+ against one provider in particular? There is a full head-to-head with our top-ranked pick in CoreAge Rx vs Human+, and every provider that outranks it is listed on the Human+ alternatives ranking.

More providers we track (24)

514 more are filed too — see every provider we track, ranked.

Pricing, states and verification reflect Human+'s public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Human+'s site. Not medical advice; see our disclosure.

← Back to all rankings